Stocks›Healthcare›MRNA

MRNA

Moderna, Inc.

NasdaqResearch view

Healthcare · Biological Products, (No Diagnostic Substances) · Large-cap · SEC EDGAR FY 2025-12-31

Price history

Chart: TradingView’s own feed · page prices: 1D EOD

🔒 Click to interact · scroll moves the page

The record

LAST 90 DAYS · 1D EOD

After a story on MRNA, the first close moved a median −3.35%. Up 0 of 3; over the three sessions after that, a median +2.79%.

consumer2−3.82%earnings1−1.85%

Aug 28Moderna (MRNA), Merck (MRK) Cancer Vaccine Wins in Late-Stage TrialYahoo Finance−3.35%1D
Aug 23Moderna (MRNA) Soars 179% as Melanoma Therapy Candidate Rewrites Growth StoryYahoo Finance−4.30%1D
Jul 10Stock Market Today: Dow Ends Higher; SK Hynix Jumps In U.S. Trading Debut; Moderna TumblesYahoo Finance−1.85%1D

Reaction = the first close after the story against the close before it. Prior-session closes only; not a call, not advice.

Snapshot

SEC EDGAR · FY 2025-12-31

SectorHealthcare

Market Cap$57.4B

Enterprise Value$55.4B

Income$-2.8B

Sales$1.9B

Book/sh$21.67

Cash/sh$6.50

Dividend TTM—

Payout—

Employees—

IPO—

Quick Ratio3.22

Current Ratio3.29

Debt/Eq0.07

EPS (ttm)$-7.26

EPS this Y21.8%

EPS past 3/5Y—

Sales past 3/5Y-53.4%

EPS Y/Y TTM21.8%

Sales Y/Y TTM-39.9%

Shs Outstand399.24M

ROA-22.9%

ROE-32.6%

ROIC-47.2%

Gross Margin—

Oper. Margin-158.1%

Profit Margin-145.2%

Every figure here is filed with the SEC. Valuation and estimate metrics (P/E, PEG, EV/EBITDA, price targets, forward EPS) are omitted until our market-data feed is licensed for display — we’d rather show fewer numbers than blank ones. Deeper lines (cash flow, balance sheet) below.

Revenue & Earnings — fiscal year

$18.5B

2021

$19.3B

2022

$6.8B

2023

$3.2B

2024

$1.9B

2025

Financials — annual

SEC EDGAR · last 5 FY · tap a row to explain it

USD	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	$18.5B	$19.3B	$6.8B	$3.2B	$1.9B
Gross Profit	—	—	—	—	—
Operating Income	$13.3B	$9.4B	$-4.2B	$-3.9B	$-3.1B
Net Income	$12.2B	$8.4B	$-4.7B	$-3.6B	$-2.8B
Diluted EPS	$28.29	$20.12	$-12.33	$-9.28	$-7.26
Operating Cash Flow	$13.6B	$5.0B	$-3.1B	$-3.0B	$-1.9B
Free Cash Flow	$13.3B	$4.6B	$-3.8B	$-4.1B	$-2.1B

Deep dive

Computed from the SEC EDGAR multi-year statements

Operating leverage — margins

GrossOperatingNet

FY25 cash-flow waterfall

Cash-flow detail unavailable in this filing.

—

COMMUNITY · $MRNA0 theses

POST YOUR TAKE →

Related Stocks

Click to explore

Same Industry · Biological Products, (No Diagnostic Substances)

GILEAD SCIENCES, INC.

NEUROCRINE BIOSCIENCES INC

HALOZYME THERAPEUTICS, INC.

Krystal Biotech, Inc.

—$10.0B

Same Sector · Healthcare

INTUITIVE SURGICAL INC

—$133.2B

VRTX

VERTEX PHARMACEUTICALS INC / MA

—$130.4B

Build basket with MRNA Screener

Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.